Vitrolife AB
SWB:VTFN

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
SWB:VTFN
Watchlist
Price: 12.91 EUR 5.47%
Market Cap: 5.7B EUR
Section:
 

Relative Value

The Relative Value of one VTFN stock under the Base Case scenario is hidden EUR. Compared to the current market price of 12.91 EUR, Vitrolife AB is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VTFN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
93
vs Industry
55
Median 3Y
7.1
Median 5Y
8.7
Industry
8
Forward
5.2
More Details
41.6
P/E
P/E
Price to Earnings
41.6
vs History
69
vs Industry
4
Median 3Y
42.9
Median 5Y
61
Industry
23.5
Forward
41.2
More Details
24.7
P/OCF
P/OCF
Price to OCF
24.7
vs History
95
vs Industry
7
Median 3Y
31.5
Median 5Y
40.8
Industry
21.9
More Details
43.3
P/FCFE
P/FCFE
Price to FCFE
43.3
vs History
68
vs Industry
5
Median 3Y
56.8
Median 5Y
57.3
Industry
24.3
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
84
vs Industry
46
Median 3Y
1.7
Median 5Y
2
Industry
3.2
More Details
5.5
EV/S
EV/S
Enterprise Value to Sales
5.5
vs History
93
vs Industry
45
Median 3Y
7.4
Median 5Y
9.1
Industry
8.1
Forward
5.4
More Details
9.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.3
vs History
93
vs Industry
36
Median 3Y
13.1
Median 5Y
15.9
Industry
10.1
More Details
29.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
29.3
vs History
58
vs Industry
5
Median 3Y
28.8
Median 5Y
31.7
Industry
5.9
Forward
17.9
More Details
29.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.3
vs History
71
vs Industry
5
Median 3Y
30.3
Median 5Y
40.5
Industry
6.2
Forward
27.4
More Details
25.9
EV/OCF
EV/OCF
Enterprise Value to OCF
25.9
vs History
95
vs Industry
6
Median 3Y
32.7
Median 5Y
42.2
Industry
7.7
More Details
41.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
41.1
vs History
73
vs Industry
4
Median 3Y
42.8
Median 5Y
49.2
Industry
6.3
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
85
vs Industry
51
Median 3Y
1.5
Median 5Y
1.7
Industry
5.6
More Details

Multiples Across Competitors

VTFN Competitors Multiples
Vitrolife AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Vitrolife AB
SWB:VTFN
18.4B EUR 5.2 41.6 29.3 29.3
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 254 975 585.5 -17 510 082.5 -17 182 753 -17 144 504.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 968 621.2 -161 447.8 -196 049.2 -193 812
US
Abbvie Inc
NYSE:ABBV
404.7B USD 6.7 170.9 16.7 23.6
US
Amgen Inc
NASDAQ:AMGN
181.6B USD 5 25.8 18.6 18.6
US
Gilead Sciences Inc
NASDAQ:GILD
153.6B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.2B USD 10.4 33.3 24.7 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.9 -529.2 -576.3 -560.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
85B USD 6 18.6 17.8 20.2
AU
CSL Ltd
ASX:CSL
84.5B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
55.2B USD 17.2 1 266.1 170.8 207.1
P/S Multiple
Revenue Growth P/S to Growth
SE
Vitrolife AB
SWB:VTFN
Average P/S: 26 267 849.1
5.2
4%
1.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
254 975 585.5
140%
1 821 254.2
FR
Pharnext SCA
OTC:PNEXF
33 968 621.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 073.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
6
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.2
46%
0.4
P/E Multiple
Earnings Growth PEG
SE
Vitrolife AB
SWB:VTFN
Average P/E: 199.3
41.6
11%
3.8
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 510 082.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 447.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
10%
1.9
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 266.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Vitrolife AB
SWB:VTFN
Average EV/EBITDA: 37.9
29.3
3%
9.8
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 182 753 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 049.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.6
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
170.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Vitrolife AB
SWB:VTFN
Average EV/EBIT: 44.1
29.3
8%
3.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 144 504.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 812 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.2
13%
1.6
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
207.1
N/A N/A

See Also

Summary
VTFN intrinsic value, competitors valuation, and company profile.
DCF Valuation
VTFN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VTFN stock valuation using valuation multiples.
Wall Street Estimates
VTFN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VTFN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.